HoyleCohen’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

HoyleCohen’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$7.61K	Hold	14,000	–	–	﹤0.01%	274
2024 Q1	$14.3K	Hold	14,000	–	–	﹤0.01%	281
2023 Q4	$7.98K	Hold	14,000	–	–	﹤0.01%	270
2023 Q3	$14.6K	Hold	14,000	–	–	﹤0.01%	259
2023 Q2	$19.7K	Hold	14,000	–	–	﹤0.01%	260
2023 Q1	$22.3K	Hold	14,000	–	–	﹤0.01%	258
2022 Q4	$20.4K	Hold	14,000	–	–	﹤0.01%	263
2022 Q3	$60K	Hold	14,000	–	–	0.01%	253
2022 Q2	$54K	Hold	14,000	–	–	0.01%	255
2022 Q1	$67K	Hold	14,000	–	–	0.01%	270
2021 Q4	$51K	Hold	14,000	–	–	﹤0.01%	273
2021 Q3	$112K	Hold	14,000	–	–	0.01%	263
2021 Q2	$159	Hold	14,000	–	–	0.01%	262
2021 Q1	$130K	Buy	+14,000	New	+$146K	0.01%	261

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HoyleCohen's VIRX Position: Q2 2024 in Review

HoyleCohen held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q2 2024 at 14,000 shares worth $7.61K. The position accounts for ﹤0.01% of the portfolio, ranked #274.

HoyleCohen first reported a position in VIRX in Q1 2021 and has held it in 14 quarters since. The position peaked at $130K in Q1 2021. 40 funds tracked by Wall St. Rank hold VIRX as of Q2 2024.

HoyleCohen held 14,000 shares of Viracta Therapeutics, Inc. Common Stock worth $7.61K as of Q2 2024.
HoyleCohen left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q2 2024.
Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of HoyleCohen's portfolio in Q2 2024, its #274 holding.
HoyleCohen first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 14 quarters since.
HoyleCohen's Viracta Therapeutics, Inc. Common Stock position peaked at $130K in Q1 2021.
40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2024.

Based on HoyleCohen's 13F filing for Q2 2024, filed 19 Jul 2024.